Bacteremia Clinical Trial
Official title:
Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols
The first time the American Heart Association (AHA) suggested that disinfection of the
gingival sulcus be performed as a complement to antibiotic prophylaxis in patients
considered to be at risk of Infective endocarditis (IE) was in their protocol for the
prevention of IE published in 1977. This practice was included by the AHA and adopted by
other expert committees such as the British Society for Antimicrobial Chemotherapy (BSAC) in
subsequent prophylactic regimens. In 1992, the BSAC specified the presentation and
concentration of chlorhexidine (CHX) that should be used before starting the dental
procedure: 1% gel at the gingival margin or 0.2% mouthwash for five minutes. In 1997, the
AHA recognised the need to use antiseptic mouthwashes (CHX or povidone iodine) prior to
dental manipulations, although they recommended against the use of gingival irrigators and
against the continuous use of antiseptics in order to avoid the selection of resistant
micro-organisms In 2006, the BSAC recommended a single mouthwash with 0.2% CHX gluconate (10
ml for 1 minute) before performing dental procedures associated with bacteraemia in patients
at risk of IE. In contrast, in 2007, the AHA recommended against the use of any antiseptic
prophylaxis protocol.
In 2008, the National Institute for Health and Clinical Excellence of the United Kingdom
recently performed a systematic review of the antimicrobial prophylaxis protocols for IE and
reported that: "Oral chlorhexidine used as an oral rinse does not significantly reduce the
level of bacteraemia following dental procedures". This conclusion was reached after
analysis of numerous studies on the efficacy of prophylaxis with CHX for the prevention of
post-dental manipulation bacteraemia. However, those studies presented significant
methodological differences not only in the dental procedures performed, but also in the
concentration of CHX applied and the method of application of the antiseptic solution
(mouthwash and/or irrigation), making comparison of the results of the different series
difficult.
There are few studies that have analysed the efficacy of the mouthwash of 0.2% CHX (the
concentration recommended by the BSAC) in the prevention of post-extraction bacteraemia.
Only one study analysed the combination of local irrigation and mouthwash with chlorhexidine
before dental extraction, but with a really lower concentration of CHX, only 0.02%.
The objective of this study is to investigate the prevalence, duration and aetiology of
bacteraemia secondary to a single tooth extraction after prophylaxis with different CHX
protocols.
The study group will be formed of patients undergoing tooth extraction under local
anaesthesia in the Department of Stomatology and Maxillofacial Surgery of the Santo Antonio
General Hospital (Oporto, Portugal).The following exclusion criteria will be applied:
patients under 18 years of age; antibiotic treatment in the previous three months; routine
use of oral antiseptics; and any type of congenital or acquired immunodeficiency or other
disease that can favour the onset of infection or haemorrhagic complications. Applying these
criteria and after a statistic power test, the sample will be 208 patients. The select
patients will be attributed randomly a number of participation and they will be distributed
into four groups:
- Control Group: 52 patients who will use no prophylactic chlorhexidine (CHX) regimen.
- CHX mouthwash group (CHX-MW group): 52 patients who will perform a mouthwash with 0.2%
CHX (10 ml for 1 minute, BSAC recommendations) (Oraldine Perio®, Johnson and Johnson,
Barcelona, Spain) before the tooth extraction.
- CHX mouthwash/subgingival irrigation group (CHX-MW/SUB_IR group): 52 patients who will
perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who then
will undergo subgingival irrigation with 1% CHX on the tooth to be extracted; the
irrigation will be done with the Heraeus Citojet Intraligamental Syringe (CIS) (Kulzer
Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular
surface and 3 on the palatine surface).
- CHX mouthwash/supragingival irrigation group (CHX-MW/SUPRA_IR group): 52 patients who
will perform a mouthwash with 0.2% CHX (10 ml for 1 minute) (Oraldine Perio®) and who
then will undergo supragingival irrigation with 1% CHX on the tooth to be extracted;
the irrigation will be done continuously around the tooth to be extracted by a
conventional syringe.
The mouthwash and subgingival or supragingival irrigation will be performed before injection
of the local anaesthetic.
After recording the sex and age of each patient, a single dentist will perform an intraoral
examination 2 days before the intervention, collecting the following information: plaque
deposits (simplified Greene and Vermillion oral hygiene index) , calculus deposits (Ramfjord
calculus index), presence of gingival bleeding (Löe and Silness gingival index), depth of
periodontal pockets (Ramfjord index), degree of tooth mobility (Ramfjord tooth mobility
index), number of caries (including root remnants), and presence of submucosal abscesses,
fistulae and periapical foci detected clinically and/or radiologically. Each patient will be
assigned an overall oral health status using a scale designed by the authors and published
previously; the scale incorporates dental and periodontal health criteria.
Local anaesthesia will be administered to all patients using conventional techniques
(regional block and/or infiltration). The anaesthetic will be lidocaine plus adrenaline
(1:100,000) and not more than 2 cartridges in any patient.
The prevalence of baseline bacteraemia will be determined by collection of a peripheral
venous blood sample (10 ml) from each patient before performing any manipulation. The
prevalence of bacteraemia secondary to a mouthwash and subgingival or supragingival
irrigation will be determined by the collection of a peripheral blood sample (10 ml) 30
seconds after each of these actions. Further samples (10 ml) will be drawn 30 seconds and 15
minutes after completion of the tooth extraction in order to determine the prevalence and
duration of post-extraction bacteraemia.
Intravenous access will established using an 18-22 gauge "angiocath" catheter (Becton
Dickinson, Sparks, MD, USA) inserted in the antecubital fossa or dorsum of the hand after
disinfection of the area with alcohol and povidone iodine. The catheter will be flushed with
3 ml of saline after each extraction and the first 2 ml of blood was discarded. Equal
volumes of each sample will be inoculated into two bottles containing aerobic and anaerobic
culture media (Bactec Plus, Becton Dickinson), and the bottles will be immediately
transferred to the laboratory. The whole process of manipulation and transport of the
samples will be performed in accordance with the recommendations of the Spanish Society of
Infectious Diseases and Clinical Microbiology.
The blood culture bottles into which the blood samples will be injected and processed in the
Bactec 9240 (Becton Dickinson). Gram stain will be performed on all positive cultures. The
positive aerobic blood cultures will be subcultured on blood agar and chocolate agar in an
atmosphere with 5%-10% CO2, and on MacConkey agar under aerobic conditions. The same
protocol will be used for the positive anaerobic blood cultures but include subculture on
Schaedler agar and incubation under anaerobic conditions. The bacteria isolated will be
identified using the battery of biochemical tests provided by the Vitek system (bioMérieux
Inc., Hazelwood, Missouri, USA) for gram-positive bacteria, Neisseria spp./Haemophilus spp.
and obligate anaerobic bacteria. Applying the Ruoff criteria, Streptococcus viridans will be
classified into five groups: mutans, salivarius, bovis, anginosus and mitis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |